Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer

PURPOSE: Breast cancer is the most common cancer among women. Pemetrexed, a new generation antifolate drug, is one of the primary treatments for breast cancer. However, multidrug resistance (MDR) in breast cancer greatly hampers the therapeutic efficacy of chemotherapies such as pemetrexed. Nanomedi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Fang, Yin, You, Chen, Ting, Chen, Jihui, Ge, Meixin, Lu, Yunshu, Xie, Fangyuan, Zhang, Jian, Wu, Kejin, Liu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846754/
https://www.ncbi.nlm.nih.gov/pubmed/29563790
http://dx.doi.org/10.2147/IJN.S150237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846754/
https://www.ncbi.nlm.nih.gov/pubmed/29563790
http://dx.doi.org/10.2147/IJN.S150237

Ejemplares similares